SDOG250117P49000
- 0.00
- 0.000.00%
Alps Etf Trust Sector Dividend Dogs Etf Newsroom
The list of preferred chip stocks for 2025 has been revealed! In addition to NVIDIA and Broadcom, Wall Street's major firms are also bullish on these companies.
Analysts at Bank of America expect the overall sales of the Semiconductors market to grow by about 15% in 2025, building on the strong growth projected for 2024, reaching 725 billion dollars. Although this growth rate is slower compared to this year's forecast of 20%, it remains very strong and robust.
American Airlines Lifts Christmas Eve Grounding, Shares Bounce Back
American Airlines Resumes Flights in the U.S. and Averts the Southwest Airlines Holiday Meltdown of 2022
Saying one thing and doing another? Europe's imports of Russian LNG have reached a record high.
The EU vows to eliminate its dependence on Russian chemical fuels, but ultimately cannot resist the temptation of Low Stock Price. However, to appease Trump, Europe may increase imports from the USA going forward.
Pfizer (PFE.US) cancer small molecule combination therapy has received accelerated approval from the FDA.
Pfizer (PFE.US) recently announced that the USA FDA has expedited the approval of the BRAF inhibitor Braftovi (encorafenib) in combination with Erbitux (cetuximab) and the mFOLFOX6 treatment regimen (which includes fluorouracil, leucovorin, and oxaliplatin) for the treatment of patients with metastatic colorectal cancer (mCRC) who have been tested positive for the BRAF V600E mutation.
Bristol-Myers Squibb (BMY.US) TYK2 inhibitors have achieved the primary endpoints in two key phase 3 clinical trials.
Bristol-Myers Squibb (BMY.US) announced today the positive results of the POETYK PsA-1 and POETYK PsA-2 trials. These two key Phase 3 clinical trials evaluated the efficacy and safety of the tyrosine kinase 2 (TYK2) inhibitor Sotyktu (deucravacitinib) in adult patients with active psoriatic arthritis (PsA).
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
Analyst Expectations For Darden Restaurants's Future
Morgan Stanley Maintains Overweight on Darden Restaurants, Raises Price Target to $209
Bristol Myers Squibb's Sotyktu Shows Results in Psoriatic Arthritis Trials
Bristol Myers Squibb Wins EU Approval for New Colorectal Cancer Treatment
Too much increase! Hedge Funds are starting to reduce their holdings in USA Nuclear Power stocks.
Recently, with the strong rebound of Nuclear Power stocks, some hedge fund managers have started to be cautious about their high valuations and have reduced their exposure to Nuclear Power stocks. However, Guy Keller, the portfolio manager at Tribeca, also stated that he would never establish short positions.
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
A retrospective on the OpenAI series of conferences: From tools to AGI, the evolution of OpenAI in 12 days.
In the first four days, the official version of o1, Sora, and Canvas were launched with great impact; after a few days of 'silence' in between, the last day directly revealed a game-changer—GPT-o3, which broke the skepticism surrounding the bottleneck in AI development.
Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings
Darden Restaurants' Diversified Portfolio And Uber Delivery Partnership Offer Confidence In Overcoming Fine Dining Challenges: Analysts
FDA Grants Accelerated Approval To Encorafenib With Cetuximab And MFOLFOX6 For Metastatic Colorectal Cancer With A BRAF V600E Mutation